Direct oral anticoagulants in patients with hematologic malignanciesAlessandra Serrao, Antonio Chistolini, Luciano Fiori et al.|Hematological Oncology|2020Cited by 14
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?Roberto Latagliata, Robin Foà, Matteo Molica et al.|European Journal Of Haematology|2018Cited by 6
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significanceSara Mohamed, Marco Mancini, Roberto Latagliata et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 2
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center CohortSofia Chiatamone Ranieri, Roberto Latagliata, Maria Antonietta Arleo et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 2
Author response for "Direct Oral Anticoagulants In Patients With Hematologic Malignancies"Alessandra Serrao, Antonio Chistolini, Luciano Fiori et al.|Unknown|2020Cited by 0